Purpose: To assess the risk and time course of oral bisphosphonate-induced osteonecrosis of the jaws.
[Boniva; Roche Laboratories, Basel, Switzerland]) demonstrate a risk for osteonecrosis as well. Initial reports of bisphosphonate-induced osteonecrosis of the jaws focused on those cases caused by either Zometa or Aredia used to stabilize metastatic cancer G deposits in bone. l -Nevertheless, several of these publications also reported a smaller number of cases related to oral bisphosphonates used in the treatment of osteopenia and osteoporosis 2 ._' 1 and since then there have been more publications relating osteone crosis in patients using oral bisphosphonates. 7 -9 How ever, few details were provided and no distinctions concerning the incidence, severity, risks, prevention, or treatment outcomes between the intravenous bisphosphonate cases and the oral bisphosphonate cases were even attempted. The purpose of this arti cle is to present data from 30 cases of oral bisphos phonate-induced osteonecrosis of the jaws contrast ing it to the data we have accumulated in 116 cases of intravenous bisphosphonate-induced osteonecrosis cases related to risk factors, prediction of risk, pre vention recommendations, and treatment recommen dations. The purpose of this paper is also to introduce the morning fasting serum e-terminal telopeptide (CTX) bone turnover marker as a useful clinical tool to help assess risk, and guide the clinician's evalua tions of nonsurgical treatment response as well as to guide decisions as to when surgery can be accom plished with the least risk.
Materials and Methods
Thirty consecutive cases of exposed bone in the mandible or maxilla that fit the American Association of Oral and Maxillofacial Surgeons Task Force defini tion of bispbosphonate-induced osteonecrosis 10 were prospectively included in this data set. The case def inition is as follows: the presence of nonhealing ex posed bone in the maxilla or mandible that has per sisted for more than 8 weeks in a patient who has received a systemic bisphosphonate but has not re ceived local radiation therapy.
Each included patient was asked for a detailed his tory concerning the oral bisphosphonatc used, the dose, the frequency, the duration of bisphosphonate therapy, comorbidities, and the indication for the bisphosphonate. Each patient was also surveyed con cerning any initiating event that produced the ex posed bone, the presence of pain, previous treatment for the exposed bone and whether a response was achieved, and if the hisphosphonate was discontin ued. Each patient was then givcn a comprehensive oral examination noting the size and location of the exposed bone as well as signs of seCOnclal1' infection. Each patient was also consented and scheduled for a fasting morning blood draw of 1 mL of whole blood ORAL BISPIIOSPHONATE-INDUCED OSTEONECROSIS for a CTX bone turnover marker assessment as part of their regular osteoporosis follow-up. Each patient pro ceeded to receive nonsurgical management with ei ther 0.12% chlorhexidine initially or 0.12% chlorhexi dine combined with an antibiotic; penicillin VK 500 mg 4 times daily if not allergic or Levaquin (Ortho McNeil Inc, Raritan, N]) 500 mg once daily if they were allergic to penicillin. The advanced presentation cases and cases refractory to nonsurgical management were resolved with surgical debridements or resec tions as appropriately gUided by the CTX values.
Results
The data concerning the type of oral bisphospho nate, the dose, the frequency, the duration, indica tions for the bisphosphonate, comorbidities, location, and the size of the exposed bone are presented in Tahle 1. Twenty-seven cases (90%) resulted from Fosamax use with the mean duration of drug expo sure of 5.7 years and 3 from Actonel 00%) use with a mean duration of exposure of 5.0 years. All cases occurred in women at a mean age of 64.8 years. Twenty-eight of the 30 patients took their oral bisphosphonate on a once weekly schedule; Fosamax at 70 mg/wk or Actonel at 35 mg/wk. Two patients took Fosamax 10 mg daily. Sixteen patients (53.3%) were taking their oral bisphosphonate for osteopenia as diagnosed by their prescribing physician and with a bone mineral density (BMD) T-score of greater than -2.5. II Ten patients (33%) took their oral bisphospho nate for osteoporosis as diagnosed by their prescrib ing physician and had HMD values relating a T-scorc of less than _2.5,12 7 others 03.4%) took their bisphos phonates for steroid-induced osteoporosis for which each had concomitantly taken prednisone, and 3 also took methotrexate at varying doses for more than 4 years in treatment of an autoimmune condition.
Twenty nine cases (96.7%) occurred in the mandi ble while only 1 case (3.3%) occurred in the maxilla. Spontaneous bone exposures of the lingual cortex in the molar area occurred in 13 cases (43.4%) (Fig 1) . One spontaneous bone exposure (3.3%) occurred at the buccal cortex unrelated to a torus and another 1 (3.3%) occurred exposing a huccal torus (Fig 2) . Eleven cases (36.7%) resulted from an extraction of a mandibular molar tooth and 1 (3.3%) from the re moval of scveral anterior mandibular teeth. Two cases (6.7%) developed as a result of dental implant place ments (Fig 3) and another 1 (3.3%) from harvesting a palatal connective tissue graft (Fig 4) . Therefore, 15 cases (50%) of oral bisphosphonate-incluced osteone crosis occurred spontaneously without a recognized initiating event and anothcr 15 cases (50%) occurre as the result of an invasive dental procedure. ported pain. There was also an exponential relation ship between the size of the bone exposure and the duration of oral bisphosphonatc usc ( fig 5) . The data concerning the fasting serum CTX bone turnover marker values are presented in Table 3 . Seventeen of the 30 patients who presented with an oral bisphosphonate-induced osteonecrosis were still taking their oral bisphosphonate at the time of their presentation. Those 17 patients had CTX values that ranged from 30 pg/mL to 102 pg/mL with a mean of 72.9 pg/mL. After 6 months of discontinuation ("drug ' )1 nts in a patirr t \V' () ref V,'l F:Jrr:IT""": f. ' Detailed recorlls and data collection from this pro spective study of 30 patients generated consillerable data. The first consideration that must be malic is that although these 30 patients represent a relatively large series for this rare condition, they rcprescnt a vcry small percentage of patients taking oral bisphospho nates. Although the actual number of individuals tak ing oral bisphosphonates annually is unknown, Neff'5 has related that 13'){, to 18% of women in the Unitell The subgroup ofU patients that discontinued their oral bisphosphonate (drug holiday) before presenting to our facility were also evaluated with morning fast ing serum CTX stullies. Their data subset is presented in Tabie 4 and Figure 13 . Their CTX values ranged from 153 pg/mL to 303 pg/mL and correlated to the length of time of their drug holiday. Although no base-line reference points of their CTX values while taking the oral bisphosphonate \vere available, their improvement of CTX values across this group sho'ws a linear correlation corresponding to a monthly im provement of 26.4 pg/mL per month of drug holiday. This compares favorably with the monthly improve ment of 25.9 pg/mL calculated for the subgroup of the 17 patients that were discontinued from the oral bisphosphonate after a baseline crx value could be obtained. 3 2 a ' ------------ Eleven patients experienced resolution of their os teonecrosis without surgcIT (Figs 11, 12) . Five spon taneously sequestered a bone fragment and 6 resorbed their exposed bone, all eventuating into a complete mucosal cover. The mean CTX value for this group was 245.8 pg/mL after a drug holiday of 3 months to 9 months. All 3 patients who had received concomitant prednisone and methotrexate com pletely healed their exposed bone. However, 1 pa tient improved with '50% of their original exposed bone coverell by healthy-appearing mucosa at 1 year and complete healing by 1.5 years. The CTX values for the 2 that spontaneously healed within 9 months were 204 pg/mL and 196 pg/mL respectively. The CTX value for the prednisone patient that had not an additional 37% to 50% have osteopenia. Therefore, even though the number of patients receiving oral bisphosphonates is unknown, the number is in the tens of millions. These 30 patients represent only 1 center's experience; the data presented here should not be used to extrapolate prevalence.
Ninety percent of our cases were caused by Fosa max and lO'X, by Actonel. On one hand this higber incidence related to Fosamax may be biased due to a greater utilization of fosamax in the public sector. Another possible explanation is dose, potency, ab sorption, and half life in bone. The weekly dose of Actoncl is only 35 mg, while the weekly dose of fosamax is 70 mg. Fosamax is considered the most potent of the oral bisphosphonates and actually is as potent as the intravenous bisphosphonate Aredia, which can partly explain the higher incidence related to Fosamax. I i Fosamax and other oral bisphospho nates produce a lesser incidence of osteonecrosis and a lesser severity than intravenous bisphosphonates because they are not well-absorbed orally. Both Fosa max and Actonel have a bioavailability of only 0.70% in women and 0.59% in men (a published average bioavailability of 0.64%) under ideal conditions. I ~. 16 In addition. patients often do not take their medica tions as directed leading to variable absorption rates and a fUlther reduction in bioavailability which may accollnt for the observed variabilities in risk and se- verity between individuals, Finally, the terminal half life in bone for each oral bisphosphonate is not pre cisely known, While it is known that the terminal half life in bone is greater than 10 years 17 and it has been suggested that Fosamax has a somewhat longer half life in bone than Actonel, this long half life itself precludes an accurate determination beyond this time. Therefore, the difference in the incidence of osteonecrosis between the 3 oral bisphosphonates in use today relates to its accumulation and retention in bone and a clear explanation as to why there are differences may never be completely known.
The data clearly indicate that the time over which a patient takes an oral bisphosphonate (accumulation in bone) is the most critical factor. All patients who developed osteonecrosis took an oral bisphosphonate for more than 3 years. ]\'loreover, the data indicate that most cases developed after 5 years or more of drug exposure and that the incidence and severity increased linearly with exposures over 3 years. This is substantially different from osteonecrosis cases caused by intravenous bisphosphonates which IT quires only a mean of 9.3 months for Zometa and 14.1 months for Aredia to develop exposed bone? This faster development of exposed bone is due to the intravenous route which bypasses the low and vari able gut absorption of oral bisphosphonates so that after about 40'% is cleared in the urine the remainder of the intravenous dose accumulates in bone.
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,) It is likely that the rapid and high dose accumulation in bone from the intravenous bisphosphonates not only induces apoptosis of a large population of osteoclasts but its repeated dosing exhausts the ability of the bone marrow to replenish the osteoclasts from the pool of osteoclast precursors. Comparatively, the poor absorption of oral hisphosphonates represents only a gradual accumulation in bone and thus may effect the osteoclasts less severely. In addition, their gradual accumulation in bone allows the bone mar row to keep pace with the loss of osteoclasts thus delaying the onset of clinicillly exposed bone, reduc ing its severity, and allowing a recovery once the drug is discontinued.
It is not unexpected that all patients in this study were women and that the mean age was 64.8 years. These facts are related to the osteopenia/osteoporosis indication for oral bisphosphonates and underscores the fact that oral bisphosphonate-induced osteonecl'O ORAL BISPHOSPHONATE-INDUCED OSTEONECROSIS sis of the jaws is mostly a women's health cOI1l:ern and mostly that of postmenopausal women. Even ste roid-induced osteoporosis has a prevalence for women because the more common autoimmune dis eases such as rheumatoid arthritis and systemic lupus erythematosus have a strong predilection for women. This differs somewhat from osteonecrosis cases caused by intravenous bisphosphonates due to their indications. That is. a smaller bias toward women is present in this group due to the frequent use of intravenous bisphosphonates for female breast can cers that have devclopcd bony metastasis and that male breast cancer is very rare. However, this is some what offset by the remaining indications for intrave nous bisphosphonates which include bony metasta scs mostly from multiple myeloma, and to a lesser extent from lung cancers and prostate cancers all of which have a predilection for men. Despite the bias toward men for these conditions, tile incidence of intravenous bisphosphonate-in<.luced osteonecrosis in our database is 70% women.
Oral bisphosphonate-induced osteonecrosis uevel opeu evenly divided between spontaneous bone ex posures and traumatically initiated bone exposures. This contrasts with the experiencc from intravenous bisphosphonates in which only 25% of cases devel oped spontaneously. This is 1110st likely due to the fact that the intravenous bisphosphonatcs accumulate in bone much faster creating a more rapid and mort: insidious bone turnover suppression. It is also con tributed to by the fact that the oral hygiene and periodontal condition was observed to be worse in While the molar region of the mandible is also the most common location for an intravenous bisphos phonate-induced osteonecrosis it is not at the strik ingly high predilection as now documcnted in oral bisphosphonate-induced osteonecrosis (41.2% to 93.7%).
The predilection for the molar arca in general and the mandibular molar area specifically is common to all types of bisphosphonates by virtue of tlleir basic mechanism of action. Because all bisphosphonates cause reversible amI/or irreversible osteoclast dys function they slow down and may even halt bone resorption altogether. 2021 This antiresorptive effect is therapeutic up to a point as proven by their ability to resist cancer-related bone resorption and to slow down the loss of bone mass and even increase bone mass in osteopenia and osteoporosis. However, be yond the therapeutic range of any drug lurks toxicity. Too great of an accumulation of a bisphosphonate in bone will cause a significant shut down in bone turn over. That is, by inhibition of osteoclasts bone re newal is prevented. This is due to the known role of the osteoclast as a cell which resorbs old bone con taining dead or old osteocytes and microfractures and in doing so releases cytokines such as bone morpho genetic protein and insulin-like growth factors 1 ,U1d 2 which induce new bone formation. This new bone is more cellular and less mineral and more clastic. As it ages, this bone will also become less cellular, more mineralized, less clastic and will then die off to be come resorbed itself and be replaced by yet another generation of bone. Therefore, the rate of bone turn over in any bone directly relates to its vulnerability to bisphosphonates. The mandibular alveolar bone turn over rate is LO times that of long bones like the tibia.
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-2 \ This is the most likely explanation for the exclusive preponderance for bisphosphonate induced osteonecrosis to occur in the jaws. In addi tion, the rate of alveolar bone turnover at the crest is twice the rate of the bone turnover about the man- tlibular canal and 3 to 5 times that of the bone about the inferior border. 22 This explains why both intrave nous bisphosphonates and oral bisphosphonates ex posed bone begins in the alveolar bone. It is apparent that occlusal or denture-related compression on the alveolar bone which is greatest in the molar region and creates a more active bone turnover produces a greater vulnerability to drugs that affect osteoclast function over a prolonged period.
The presence of pain correlated directly to evi dence of infection confirming the concept that non vital bone by itself is deinnervated and nonpainful. The pain arises from secondary infections which pro voke an inl1ammatory response that elaborates the mediators of pain. This is identical to the association of pain from the exposed bone caused by the intra venous bisphosphonates. Although not specifically studied, in those cases in which bone debridements were accomplished, the micro-organisms most fre quently noted were actinomyces, moraxella, and eikenella species (Fig 14) as is also seen in the ex posed bone removed from intravenous bisphospho nate-induced osteonecrosis.
The size of the bone exposure, pain, and infection, and the requirement to accomplish surgery all di rectly correlated to the length of time the patient had been taking the oral bisphosphonate Crable 2, Fig 5) . This is particularly noted by the observation that the 3 patients who required an office-based debridement had taken Fosamax 6.4 years, 7 years, and 7.2 years respectively and the patients with the most extensive bone involvement requiring a resection had taken Fosamax for 7 ..) years and 10.2 years respectiVely. In fact, the slope of the curve in Figure 5 which plots the square surface area of bone exposure against the length of time the patient had been taking the oral bisphosphonate is that of an exponential relationship with the largest bone exposures occurring after 5 years of drug use. Although these correlations were also noted in cases of osteonecrosis due to intrave nous bisphosphonates they are less clear due to the many more comorbidities associated in the intrave nous bisphosphonate patients.
THE C-TERMINAL TELOPEPTIDE DATA ANALYSIS
The morning fasting serum CTX test measures a surrogate marker of bone turnover. It is one of several known semm and urine tests that measures a break down product of hone resorption. 25 -27 The CTX spe cifically measures a specific crosslink peptide of type I collagen in bone. Type I collagen is the structural organic component of bone and accounts for 98% of the total protein in bone. The serum CTX is consid ered to best correlate to bone turnover 2H and was chosen due to the t~lCt that a single laboratol)1 (Quest Diagnostics Nichols East Lab in San Juan Capistrano, California) performs this test under standard condi tions. The telopeptide fragment in question is cleaved from the main crosslink chains of collagen by the osteoclast during bone resorption. Its level in the serum is therefore proportional to the amount of osteoclastic resorption occurring at the time the blood is drawn. Even though laborato!)' normal ranges arc said to be between 50 pg/mL and 450 pglmL, this normal range is not accurate related to the osteoporosis population. Actual normal values are usually well over 300 pg/mL and are most commonly 400 pg/mL to 550 pg/mL in patients not taking bisphospbonates. Lower values represent v,lI)'ing de grees of suppression of normal bone turnover some times also called bone remodeling or bone renewal.
The most controlled CTX data are seen in the group of 17 patients in which we accomplished a CTX test before their oral bisphosphonate was discontinued which is referred to as a "drug holiday." These data are seen in Table 3 and Figure 13 . This data subset demonstrates that the individuals who were still tak ing their oral bisphosphonate and had osteonecrosis also had severe suppression of bone turnover: mean CTX of 72.9 pg/mL. In addition, all 17 patients had CTX values less than 1 10 pg/mL. Even with a CTX day to day variability of 25% as published by Rosen et al
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and allowing for an additional margin of patient vari ability, one can say that all cases had CTX values less than 150 pg/mL. Although some of the more severe cases had very low CTX values there were too few cases to suggest a correlation between clinical sever ity and the CTX value.
Of clinical importance, the (rmonth dmg holiday Showed a direct and significant improvement in the CTX values in every patient. This improvement corre lated to either spontaneous resolution of the exposed bone, a significant improvement in the amount uf ex posed bone, or an uncomplicated healing response after surgery. It was noted that the CTX values improved at an average of 155.3 pg/mL over 6 months or a rate of 25.9 pg/mL each month. lhis rJte of improvement was con sistent with the slope of the curve seen in Figure 13 which plots the crx values against the duration of a drug holiday in the 13-patienr subgroup in which the oral bisphosphonate was discontinued at varying times prior to the CTX blood draw. This relationship appeared to be linear and was measured at 26.4 pg/mL per month. 'Olese findings are ve!)' significanr because they demon strate clinical bone recove!)' and response to a dmg holiday. It prov~s that at least part of the functioning osteoclast population can recover and be re-established from the osteoclast precursors in the bone marrow. This is a clear distinction between the ora! bisphosphonate cases and the intravenous bisphosphonate cases in which we mostly observe no improvement or response to local deblidement surgery with discontinuation of the intravenous bisphosphonate. Moreover, we have also accomplished over 60 CTX tests in cases of osteonecro sis due to intravenous bisphosphonates and have noted no direct correlations with the size of bone exposure, pain, infection, or severity. Instead, the CTX values more closely cOITelate with the control of metastatic bone deposits. This reinfurces the notion that the intra venous bisphosphonate accumulation in bone is greater than that of the oral bisphosphonates, and thar the osteoclast population is less likely to recover due to exhaustion atrophy uf the osteoclast precursors in bone. lhis may also explain why those patients who develop osteonecrosis from an intravenous bisphosphonate in the treatment of multiple myeloma arc noted to be more severe, have greater amounts of exposed bone, and arc less responsive to trearment than those with metastatic bone deposits from other cancers. That is, the intrave nous bisphosphonare suppression of bone malTOW os teoclast precursors is added to by the disease itself which replaces much of the normal bone marrow with malignant myeloma cells.
The CTX values also noted that prednisone and/or methotrexate used to treat some autoimmune dis eases caused a further suppression of bone turnover in the oral bisphosphonate cases and slowed the re cove!)' of bone turnover from the drug holiday. Nev ertheless, even in patients with a prednisone cOl11or bidity, the drug holiday was seen to produce a bone healing response measurable by the CI'X values.
Discussion
The data presented in this report concern compli cations from commonly prescribed drugs in the treat ment of a common disease: osteoporosis and its pos sible precursor osteopenia. OrJI bisphosphonate induced osteonecrosis cases are very rare and even though it is anticipated that the number will grow due to improved recognition, further repol1ing, and more patients receiving these drugs over longer periods of time, it is expected to remain a rare complication. However, patients taking oral bisphosphonates but who do not have osteonecrosis and some who already have exposed bone will still present to many clini cians who must assess the risks of invasive oral pro cedures, plan prevention strategies, and treat those cases with exposed bone. In doing so the treating dentist or oral and maxillofacial surgeon must consult with the physician treating the osteoporosis and have an understanding of the definitions of osteopenia and osteoporosis as well as the go,lls and treatment chal lenges the physician confronts in treating these enti ties.
It is estimated that 14 million women in the United States are currently diagnosed with osteopenia/osteo porosis. U It is reported that approximately 5% to 15% of patients with untreated osteoporosis eventually develop a nontrauma-related fracture usually of the femoral neck but referred to as a "hip fracture" or develop compression fractures of the vertebrae, usu ally the lumbar vertebrae...!Y-.~ I These fractures bring about pain and immobility that in this more advanced age group, frequently leads to long term and even permanent disability and sometimes even death. Therefore osteoporosis is a serious disease and a pub lic health problem.
The World Health Organization defines osteoporo sis based on the dual energy x-ray absorptiometry scan kno"vn as a DXA or DEXA scan which measures flMD in mg/cm 2 .: I0
.-12 The reference UMD value is given as an arbitrary normal at the maximum bone mineral density of a population of 22 ± 2-year-old Caucasian women ..-\..! As age and postmenopausal hor mone related reductions in bone mass occur, it is reflected as a lower UMD value or a negative value as compared with this arbitrary norm. Individual BMD values are compared with this arbitrary norm in standard devia tions. Within the range of normal is any individual who is less than 1 standard deviation below the norm. Osteopenia is defined as anyone who is between 1 and 2.5 standard deviations below the norm and os teoporosis is defined as anyone who is more than 2. ' 5 standard deviations below the norm. Severe osteopo rosis is further defined as an individual who is more than 2.5 standard deviations below the norm and also has a nontraumatic fracture. These standard devia tions are referred to as T-scores and are reported as negative numbers (eg, -1, -2.5, etc,) because they represent loss of HMD.
unfortunately, the BMD only measures bone mass not trabecular bone connectivity or bone elasticity and thcrefore does not directly or solely correlate with fracture risk5.~..H Because fracture prevention is the goal of the treating physician, the BMD value is only 1 of several factors that are considered in the treatment planning for osteoporoSiS. Other factors conSidered are race (Caucasian women are more at risk for fracture than other races), age, diet, exercise, concomitant medications, and family history. Yet the BMD value remains as the most common utilized measure of response to bisphosphonate therapy ..~~ It is important to note that in a lO-year study by Bone and Hosking et al·)6 on osteoporosis patients treated with Fosamax, 'the BMD values improved to a maxi mum at 3 years and that the group that stopped taking Fosamax at that point experienced no increase in fractures compared with the group that continued taking Fosamax and that their HMD values decreased only slightly over several years. A confirmatory study by mack et al~7 noted in a randomized double-blind controlled study of 760 women that once Fosamax had been taken for 5 years, no increase in fractures occurred after another '5 years off the drug. Thus the appropriate utilization of bisphosphonates to prevent fractures will await further dose-accumulation stud ies.
These data combined with the CTX data presented in this report indicate that drug holidays on tbe order of 4 to 6 months are reasonable, safe, and could be expected to minimize the risk of osteonecrosis (due to the anticipated rise in CTX due to increased oste oclast function) when performing invasive oral surgi cal procedures in patients taking oral bispbospho nates while also maintaining liMO values and fracture prevention related to the osteoporosis. The efficacy of thiS concept is supported by the uncomplicated heal ing and osteonecrosis resolution of the 5 patients in this study who required surgery and the improvement and nonsurgical resolution of the other cases in this study after a 4 month to 9 month drug holiday.
PREVENTION AND TREATMENT RECOMMENDATIONS
From the data gained from these studies and our clinical experience with both oral and intravenous bisphospbonate-induced osteonecrosis cases, we of fer the following recommendations.
Pre/lention
Patients first diagnosed witb osteojJenia or osteo j>orosis and are prescribed a b i:!>1>bosphonate. He cause patients taking oral bisphosphonates for less than 3 years have little risk for osteonecrosis, this allows time for the dental team to obtain optimum oral health and repair of the dentition. Similar to the recommendations already in place for a patient about to receive intravenous bisphosphonates, the treating physician is recommended to rder the patient to his/her dentist for an evaluation, treatment, and mon itoring program focused on attaining and maintaining oral health. The dental team should accomplish a complete medical and dental history and a thorough oral examination. Nonrestorable and abscessed teeth should be removed first, followed by periodontal ther apy with a recall schedule established. Root canal therapy if indicated should be acc.omplished next followed by any indicated restorative dental care and prosthodontic appliances. Little is known concerning orthodontic care at this point, but it is anticipated that adult orthodontic care is feasible and safe but may be slowed or even stopped during the first .3 years of oral bisphosphonate exposure due to the anti resorptive (antiosteoc!astic) effects of the bisphosphonate.·,H.5\>
Dental implant placements are also likely safe and will osseointegrate during thiS period. 'o However, informed consent should he provided as to an in creased risk for implant failure or osteonecrosis about the implants once the oral bisphosphonate exposure exceeds .3 years.
Patients lObo bave been taking ({II ural bi.,pbos pbOllate and jJresent for dental treatment. In this group the dentist needs to specifically ask thc patient the length of time of oral bisphosphonates use as well as the dose, the indication, and the possible w;e of concomitant steroids or other medications that might affect bone healing. In gelH:ral, nonsurgical dental procedures such as restorations, dentures, root canal therapy, dental prophylaxis, supragingival scaling, and crowns are safe at all times in hisphosphonate exposed patients. for patients who relate a history of fewer than 3 years of oral bisphosphonate use, bone healing is expected to be uncomplicated. Therefore, a serum C,TX is not required prior to an oral surgical procedure but may be used to assess the degree of hone turnover suppreSSion and/or establish a baseline value. However, if the patient relates a history of greater than 3 years of oral bisphosphonatc use or fewer than 3 years but with concomitant corticoste roid use or chemotherapy use, a CTX test is highly recommended. If the crx test is returned with a value of 150 pg/mL or greater, in our experience invasive oral surgical procedures can be accom plished with a minimal risk of osteonecrosis. If the CTX value is less than 150 pg/mL it is recommended to defer the planned surgery and to contact the pre scribing physician. It is reasonable to suggest a drug holiday with or without a substitute drug also ap proved for osteoporosis.-'(d7 Other drugs with Food and Drug Administration clearance for osteoporosiS include raloxifene (Evista; Eli Lilly, Indianapolis, IN), ORAL BISPHOSPHONATE-INDUCED OSTEONECROSIS calcitonin salmon (Miacalcin, Novartis), and recombi nant human 1-34 parathyroid hormone (rh 1-34 PTII Forteo, Eli Lilly). A drug holiday of 4 months to 6 months is recommended before a repeat CTX is ac complished. If the repeat CTX value is less than 150 pg/mL, it is recommended to extend the drug holiday with the agreement of the prescribing physician. from the data related to the rate of CTX value im provements during a drug holiday, it is unlikely that a CTX value of 150 pglmL would require more than a 6 month to 9 month drug holiday. In the rare event that the treating physician feels that a drug holiday from the oral bisphosphonate would worsen the osteopo rosis and does not want to consider a nonbisphospho nate alternative ,osteoporosis treatment, the dental team should modify its treatment plan and discuss the risks and benefits to the patient. In this rare situation, elective surgeries such as ridge augmentations, dental implant placements, tooth removals, periodontal sur gery, apicoectomies, and even adult orthodontic tooth movements are adVised only with caution. In stead, noninvasive dental care should be emphasized. If urgent invasive procedures such as removal of ab scessed or severely mobile teeth, incision and drain age of abscesses, or surgery for severe acute periodon titis arc necessary, they may be accomplished with the informed consent of the patient and the accep tance of a greater risk for osteonecrosis.
Treatment of Oral Bispbosp!Jol1ate-lndllced Osteonecrosis
Oral bisphosphonate-induced osteonecrosis is usu aUy less extensive, and more responsive to treatment than intravenous bisphosphonate-induced osteone crosis. It also correlates well to the serum CTX and is therefore more predictable. For patients who present with exposed bone due to an oral bisphosphonate we recommend that the dental provider contact the pre scribing physician and inform him/her of this compli cation and relate that the exposed hone will worsen with continued oral hisphosphonatc use. The oral bisphosphonate should be discontinued by the pre scribing physician and either a non-bisphosphonate alternative used or a complete drug holiday started. The dental team should order a morning fasting serum CTX test and begin palliative care. If the exposed bone is painless, maintenance with O. I 2'X, chlorhexi dine is all that is initially required. If the patient relates pain and/or clinical evidence of infection is present, antibiotic therapy should be provided in addition to the 0.12'X, chlorhexidine. Penicillin V-K 500 mg 4 times daily is the drug of choice due to its activity against actinomyces, eikenella, and moraxella species which arc the 3 most common species associated with secondary infections in exposed bone due to bisphosphoniltes. If the patient is allergic to penicillin Ievotlaxacin (Levaquin) 500 mg once daily is the best second line drug of choice followed hy doxycycline (Vibramycin; Pfizer Pharmaceuticals, New York, NY) 100 mg once daily, and zithromycin (Zithromax; Pfizer Pharmaceuticals) 250 mg once daily. The anti biotic regimen should extend for 14 days or until the pain is controlled and only restarted if pain returns. In patients refractory to these antibiotics the addition of metronidazole (F1agyl; Searle, Chicago, IL) 500 mg 3 times daily has proven effective. Clindamycin (Cleo cin; Pfizer Pharmaceuticals) is not n:commended due to its absent or low activity against the microorgan isms seen in bisphosphonate-induced osteonecrosis cases.
The oral and maxillofacial surgeon is urged to resist the temptation to accomplish a local debriLiement initially. Many cases of oral bisphosphonate-induced osteonecrosis will resolve without surgery during the period of the drug holiday. If the exposed bone be comes mobile or shows radiographic evidence of a sequestrum, then a local debridement can be accom plished with the anticipation of uncomplicated heal ing provided that the CTX value is greater than 150 pglmL.
SUMMARY
Oral bisphosphonate-induced osteonecrosis is a rare but real entity causeLi by the antiosteoclastic effects of bisphosphonates which inhibit bone turn over.
The clinical disease of oral bisphosphonate-induced osteonecrosis is less frequent, less severe, more pre dictable, and more n:sponsive to treatment than in travenous bisphosphonate-induced osteonecrosis.
The comorbidities of prednisone and/or methotrex ate do not produce osteonecrosis by themselves but along with a bisphosphonate will cause the osteone crosis to occur sooner, be more severe, and respond more slowly to a drug holiday.
The sel1.lm morning fasting crx bone turnover marker is a straightforward and useful tool to assess the bone turnover/renewal suppression caused by oral bisphosphonates. Its interpretation of less than 100 pg/mL as high risk, 100 pglmL to 150 pglmL as moderate risk, and greater than 150 pglmL as minimal risk provides the clinician with a useful assessment tool to predict risk and guide treatment decisions.
Oral and maxillofacial surgeons as well as all other dental proViders should respect the diagnosis of ostcopenia and osteoporosis hut should not be intim idated by the potential for complications when treat ment planning for patients taking oral hisphospho natcs. With the ability to assess the suppression of hisphosphonate-induced bone turnover by C1X mea surements and the guidelines recommenLied in this report, it is possible to provide comprehensive care with minimal risks to this group of individuals while maintaining their control of osteoporOSiS.
